Pharmaceuticals News and Research

RSS

Hospira receives positive opinion from EMA's CHMP for EC approval of Inflectra

Hospira, the world's leading provider of injectable drugs and infusion technologies, today received a positive opinion from the European Medicines Agency Committee for Medicinal Products for Human Use, recommending the European Commission approval of Inflectra (infliximab) for rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis.

28 Jun 2013

Eleven Biotherapeutics reports positive results from EBI-005 Phase 1b/2a study in patients with DED

Eleven Biotherapeutics, a biopharmaceutical company designing and engineering novel and differentiated protein-based biotherapeutics for ocular diseases, announced today positive topline clinical results from a 6-week randomized, double-masked, placebo-controlled Phase 1b/2a study of EBI-005 in patients with dry eye disease.

28 Jun 2013

Viewpoints: Late hospital bills perplex consumers; Personal health data can 'revolutionize' care

Flavio de Pecol hit the trifecta after taking his daughter to the emergency room for a horse-riding injury: hours of waiting, a 16-mile ambulance ride to a different facility and bills for more than $40,000. At least, he thought, that was the end of it. But nearly two years (later), ... De Pecol, of Newport Beach, has received yet another bill, this time for $1,054.53. ... "How can I trust that this isn't a mistake when a hospital takes 21 months to bill me?" De Pecol asked. ... Good questions, and yet another example of the way consumers are at the mercy of the healthcare industry's opaque and byzantine billing practices (David Lazarus, 6/25).

28 Jun 2013

FDA approves Novartis' Exelon Patch for treatment of severe Alzheimer's disease

The US Food and Drug Administration has expanded the approved indication for Exelon Patch (rivastigmine transdermal system) to include the treatment of people with severe Alzheimer's disease with Exelon Patch 13.3mg/24h.

28 Jun 2013

Ingestion of nanoparticles at typical environmental levels unlikely to cause overt toxicity

Ingestion of commonly encountered nanoparticles at typical environmental levels is unlikely to cause overt toxicity, according to US researchers. Nevertheless there is insufficient evidence to determine whether chronic exposures could lead to subtle alterations in intestinal immune function, protein profiles, or microbial balance.

27 Jun 2013

UCI researchers receive $2.27M to develop innovative methods of treating Type 1 diabetes.

Two UC Irvine research groups have received $2.27 million from the JDRF to develop innovative methods of treating and possibly curing Type 1 diabetes.

27 Jun 2013

Manchester researchers launch new project to better understand causes of RA

Researchers in Manchester have this week launched an innovative new project working with patients and their families to better understand the causes of rheumatoid arthritis.

27 Jun 2013

Dassault Systèmes launches industry solution experience for pharmaceutical, biotech companies

Dassault Systèmes, the 3DEXPERIENCE Company, a world leader in 3D design, 3D Digital Mock Up and Product Lifecycle Management solutions, announced today the launch of a new industry solution experience for pharmaceutical and biotech companies, "Licensed to Cure for BioPharma."

27 Jun 2013

Researchers study possible alternative medications to treat cancer-related pain

Researchers at the Brain and Spine Institute at John Theurer Cancer Center at HackensackUMC, one of the nation's 50 best hospitals for cancer, are studying a possible alternative to side effect-ridden opioid-based medications to treat cancer-related pain.

27 Jun 2013

Sprout Pharmaceuticals resubmits flibanserin NDA for treating HSDD in pre-menopausal women

Sprout Pharmaceuticals, the Raleigh-based pharmaceutical company developing flibanserin, a treatment being evaluated for Hypoactive Sexual Desire Disorder in pre-menopausal women, confirmed today that the company has resubmitted the New Drug Application for flibanserin earlier this year and expects US Food and Drug Agency action before the end of 2013.

27 Jun 2013

Kiadis Pharma to receive innovation credit from AgentschapNL to conduct Phase II study for ATIR

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that it will receive an innovation credit of up to €3 million from AgentschapNL, a division of the Dutch Ministry of Economic Affairs, to support the Phase II clinical development of Kiadis Pharma's lead pipeline product, ATIR™

26 Jun 2013

Eisai submits BELVIQ NDS with Health Canada

Arena Pharmaceuticals, Inc. announced today that Eisai Limited (based in Mississauga, Ontario), a subsidiary of Eisai Inc., has submitted a New Drug Submission for BELVIQ (lorcaserin HCl) with Health Canada.

26 Jun 2013

Mylan Pharmaceuticals launches generic version of Micronor Tablets

Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Norethindrone Tablets USP, 0.35 mg.

26 Jun 2013

Supreme Court sides with generic drug makers

The Supreme Court ruled on Monday that generic drugmakers cannot be sued under state law for adverse reactions to their products, a decision that consumer advocates called a blow to patient safety. In a 5-4 vote, the court ruled for Mutual Pharmaceutical Co, owned by Sun Pharmaceutical Industries Ltd, overturning a multimillion-dollar jury award to a badly injured patient in New Hampshire who alleged a generic drug she had taken was unsafe based on its chemical design (Hurley and Berkrot, 6/24).

26 Jun 2013

Controlled drug release using novel excipients: an interview with Dr Laura Waters, University of Huddersfield

When you take a medicine you may want the drug to all be released immediately or perhaps more slowly over a longer period of time. If we can make a medicine where we control the release then we can tailor our medicines to release at the exact rate we choose that is best for the patient.

26 Jun 2013

Highland Therapeutics subsidiary reports positive HLD-200 Phase-1 results in ADHD patients

Highland Therapeutics, Inc., a specialty pharmaceutical company based in the MaRS Discovery District in Toronto, today announced that its wholly owned subsidiary has generated positive Phase-1 results for HLD-200 - a novel formulation of methylphenidate being developed to treat the symptoms associated with Attention-Deficit/Hyperactivity Disorder.

25 Jun 2013

New study points to potential strategy for erasing memory of addiction

A new study by researchers at the Ernest Gallo Clinic and Research Center at UC San Francisco offers encouraging findings that researchers hope may one day lead to a treatment option for people who suffer from alcohol abuse disorders and other addictions.

25 Jun 2013

Infinity announces data from IPI-145 Phase 1 study in patients with advanced hematologic malignancies

Infinity Pharmaceuticals, Inc. today announced Phase 1 data from an ongoing study of IPI-145, its potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma in patients with advanced hematologic malignancies, or potentially fatal blood cancers.

25 Jun 2013

CytRx reaches targeted enrollment in aldoxorubicin Phase 2b study for treatment of soft tissue sarcoma

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, announced that it has reached the targeted enrollment of 105 evaluable patients in its international Phase 2b clinical trial with aldoxorubicin as a first-line treatment for soft tissue sarcoma.

25 Jun 2013

Robotic animals can help improve quality of life for people with dementia, says research

Robotic animals can help to improve the quality of life for people with dementia, according to new research. A study has found that interacting with a therapeutic robot companion made people with mid- to late-stage dementia less anxious and also had a positive influence on their quality of life.

24 Jun 2013

Pharmaceuticals News and Research

Hospira receives positive opinion from EMA's CHMP for EC approval of Inflectra

Eleven Biotherapeutics reports positive results from EBI-005 Phase 1b/2a study in patients with DED

Viewpoints: Late hospital bills perplex consumers; Personal health data can 'revolutionize' care

FDA approves Novartis' Exelon Patch for treatment of severe Alzheimer's disease

Ingestion of nanoparticles at typical environmental levels unlikely to cause overt toxicity

UCI researchers receive $2.27M to develop innovative methods of treating Type 1 diabetes.

Manchester researchers launch new project to better understand causes of RA

Dassault Systèmes launches industry solution experience for pharmaceutical, biotech companies

Researchers study possible alternative medications to treat cancer-related pain

Sprout Pharmaceuticals resubmits flibanserin NDA for treating HSDD in pre-menopausal women

Kiadis Pharma to receive innovation credit from AgentschapNL to conduct Phase II study for ATIR

Eisai submits BELVIQ NDS with Health Canada

Mylan Pharmaceuticals launches generic version of Micronor Tablets

Supreme Court sides with generic drug makers

Controlled drug release using novel excipients: an interview with Dr Laura Waters, University of Huddersfield

Highland Therapeutics subsidiary reports positive HLD-200 Phase-1 results in ADHD patients

New study points to potential strategy for erasing memory of addiction

Infinity announces data from IPI-145 Phase 1 study in patients with advanced hematologic malignancies

CytRx reaches targeted enrollment in aldoxorubicin Phase 2b study for treatment of soft tissue sarcoma

Robotic animals can help improve quality of life for people with dementia, says research

Industry Focus - Biopharma eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence